Abstract
VML is a lectin from Vatairea macrocarpa seeds that has various biological activities. Here, we describe three new lectin isoforms from V. macrocarpa identified through genomic DNA analysis. One of these isoforms has high similarity to VML, while another that has noteworthy differences. We have denoted the new isoforms as VML-2, VML-3 and VML-4. Recombinant VML (rVML) and VML-2 (rVML-2) were expressed in Escherichia coli and were anticipated to have similar biological activity compared to native VML. Recombinant lectins were produced using a synthetic gene strategy to improve the expression levels. We obtained two active recombinant lectin isoforms from V. macrocarpa, and there was no significant difference between their biological activities. The conservation between carbohydrate-binding sites of recombinant and native proteins was demonstrated by specific inhibition of hemagglutin activity by D-galactose and lactose. However, no inhibition was observed in the presence of glucose and mannose. Our data show that the recombinant lectins VML and VML-2 are active and capable of recognising D-galactose and lactose. Moreover, the absence of glycosylation does not interfere with their biological activity.
Keywords: Active protein, heterologous expression, isoform, lectin, legume, recombinant.
Protein & Peptide Letters
Title:Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa
Volume: 20 Issue: 11
Author(s): João Garcia Alves Filho, Antonia Sâmia Fernandes do Nascimento, Ana Cláudia Silva Gondim, Ronniery Hilario Pereira, Rodrigo Maranguape Silva da Cunha, Celso Shiniti Nagano, Edson Holanda Teixeira, Kyria Santiago Nascimento and Benildo Sousa Cavada
Affiliation:
Keywords: Active protein, heterologous expression, isoform, lectin, legume, recombinant.
Abstract: VML is a lectin from Vatairea macrocarpa seeds that has various biological activities. Here, we describe three new lectin isoforms from V. macrocarpa identified through genomic DNA analysis. One of these isoforms has high similarity to VML, while another that has noteworthy differences. We have denoted the new isoforms as VML-2, VML-3 and VML-4. Recombinant VML (rVML) and VML-2 (rVML-2) were expressed in Escherichia coli and were anticipated to have similar biological activity compared to native VML. Recombinant lectins were produced using a synthetic gene strategy to improve the expression levels. We obtained two active recombinant lectin isoforms from V. macrocarpa, and there was no significant difference between their biological activities. The conservation between carbohydrate-binding sites of recombinant and native proteins was demonstrated by specific inhibition of hemagglutin activity by D-galactose and lactose. However, no inhibition was observed in the presence of glucose and mannose. Our data show that the recombinant lectins VML and VML-2 are active and capable of recognising D-galactose and lactose. Moreover, the absence of glycosylation does not interfere with their biological activity.
Export Options
About this article
Cite this article as:
Alves Filho Garcia João, Fernandes do Nascimento Sâmia Antonia, Silva Gondim Cláudia Ana, Pereira Hilario Ronniery, Silva da Cunha Maranguape Rodrigo, Nagano Shiniti Celso, Teixeira Holanda Edson, Nascimento Santiago Kyria and Cavada Sousa Benildo, Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa, Protein & Peptide Letters 2013; 20 (11) . https://dx.doi.org/10.2174/09298665113209990049
DOI https://dx.doi.org/10.2174/09298665113209990049 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
Call for Papers in Thematic Issues
Therapeutic Proteins and Peptides of Plant Origin
Plants are still the major repository of biologically active substances. In the last two decades, however, natural peptides and proteins of plant origin have gained increasing attention due to their pharmacological activities over a variety of human illnesses, including those mediated by infections and parasitosis and those involving different cellular ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1
Current Topics in Medicinal Chemistry Phenothiazines and Related Drugs as Multi Drug Resistance Reversal Agents in Cancer Chemotherapy Mediated by p-glycoprotein
Current Cancer Therapy Reviews Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Chronic Myelogenous Leukemia
Current Cancer Therapy Reviews Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology Caffeic Acid, A Versatile Pharmacophore: An Overview
Mini-Reviews in Medicinal Chemistry Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology RNA G-Quadruplex: The New Potential Targets for Therapy
Current Topics in Medicinal Chemistry Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond
Current Medicinal Chemistry Characterizing the Relationship Between the Chemical Structures of Drugs and their Activities on Primary Cultures of Pediatric Solid Tumors
Current Medicinal Chemistry Approaches to Quantification of RNA Targets by PCR Based Techniques
Current Genomics